- Home
- SRTS vs RNXT Comparison
SRTS vs RNXT Comparison
Compare SRTS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | RNXT |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 37.0M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRTS | RNXT |
|---|---|---|
| Price | $3.05 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.00 | ★ $8.25 |
| AVG Volume (30 Days) | 37.8K | ★ 221.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | $1,123,000.00 |
| Revenue This Year | $2.00 | $194.66 |
| Revenue Next Year | $34.23 | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.66 | $0.70 |
| 52 Week High | $5.92 | $1.45 |
Technical Indicators
Market Signals| Indicator | SRTS | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 53.57 |
| Support Level | $2.82 | $0.81 |
| Resistance Level | $3.32 | $0.98 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 87.78 | 61.53 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.